SG10201408480RA - Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy - Google Patents

Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy

Info

Publication number
SG10201408480RA
SG10201408480RA SG10201408480RA SG10201408480RA SG10201408480RA SG 10201408480R A SG10201408480R A SG 10201408480RA SG 10201408480R A SG10201408480R A SG 10201408480RA SG 10201408480R A SG10201408480R A SG 10201408480RA SG 10201408480R A SG10201408480R A SG 10201408480RA
Authority
SG
Singapore
Prior art keywords
antibody
preventing
response
methods
uric acid
Prior art date
Application number
SG10201408480RA
Inventor
Theresa Rosario-Jansen
David Erick Wright
Original Assignee
Crealta Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crealta Pharmaceuticals Llc filed Critical Crealta Pharmaceuticals Llc
Publication of SG10201408480RA publication Critical patent/SG10201408480RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90688—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on other nitrogen compounds as donors (1.7)
    • G01N2333/90694—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3), e.g. uricase (1.7.3.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/107—Crystal induced conditions; Gout
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
SG10201408480RA 2009-06-25 2010-06-25 Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy SG10201408480RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26966909P 2009-06-25 2009-06-25
US24869809P 2009-10-05 2009-10-05
US29871810P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
SG10201408480RA true SG10201408480RA (en) 2015-02-27

Family

ID=43386920

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011093564A SG176897A1 (en) 2009-06-25 2010-06-25 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
SG10201408480RA SG10201408480RA (en) 2009-06-25 2010-06-25 Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011093564A SG176897A1 (en) 2009-06-25 2010-06-25 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

Country Status (17)

Country Link
US (7) US9377454B2 (en)
EP (2) EP3482768A1 (en)
JP (2) JP2012531596A (en)
KR (1) KR101861547B1 (en)
CN (1) CN102803954A (en)
AU (1) AU2010265964B2 (en)
BR (1) BRPI1010069A2 (en)
CA (1) CA2766309A1 (en)
CZ (1) CZ2011827A3 (en)
HU (1) HUP1200205A3 (en)
IL (1) IL216956A (en)
MX (1) MX347903B (en)
NZ (1) NZ597089A (en)
PL (1) PL398781A1 (en)
RU (1) RU2535038C2 (en)
SG (2) SG176897A1 (en)
WO (1) WO2010151823A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2158923E (en) 1998-08-06 2013-06-04 Univ Duke Peg-urate oxidase conjugates and use thereof
DK3321359T3 (en) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc VARIANT FORMS OF URATOXIDASIS AND ITS USE
BRPI1010069A2 (en) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "method for preventing infusion reactions during pegylated uricase therapy in patients; and method for diagnosing whether a patient treated with pegylated uricase will develop infusion reactions or develop antibody-mediated pegylated uricase release without measuring anti-peg antibody titers and pegylated anti-uricase "
US9265815B2 (en) 2011-04-29 2016-02-23 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
JP7028556B2 (en) 2013-05-03 2022-03-02 セレクタ バイオサイエンシーズ インコーポレーテッド Delivery of immunosuppressive agents with antigens for specific pharmacodynamic efficacy and induction of immune tolerance
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
MX2017002933A (en) 2014-09-07 2017-05-30 Selecta Biosciences Inc Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses.
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CN107614007B (en) 2015-05-15 2022-03-25 免疫医疗有限责任公司 Improved uricase sequences and methods of treatment
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2019010369A1 (en) 2017-07-07 2019-01-10 Allena Pharmaceuticals, Inc. Recombinant uricase enzyme
US20200237880A1 (en) * 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP3980784A1 (en) * 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
WO2021042055A1 (en) * 2019-08-30 2021-03-04 Horizon Pharma Rheumatology Llc Pegloticase for treatment of gout in renal transplant recipients

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279489C (en)
DE279486C (en)
US1016095A (en) 1910-09-08 1912-01-30 Gen Electric Splicing-sleeve.
US1141973A (en) 1911-05-22 1915-06-08 Jesse W Nichols Can-cap with vent-shield.
DE837379C (en) 1950-04-20 1955-08-16 Nordwind G M B H Wind power plant, in particular for driving a piston pump
US3451996A (en) 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US3613231A (en) 1969-07-25 1971-10-19 Paul F Pugh Method for manufacturing high voltage cable systems
US3931399A (en) 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4027676A (en) 1975-01-07 1977-06-07 Ethicon, Inc. Coated sutures
US4169764A (en) 1975-08-13 1979-10-02 Ajinomoto Co., Inc. Process for production of urokinase
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4064010A (en) 1976-07-21 1977-12-20 Eastman Kodak Company Purification of uricase
US4301153A (en) 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
US4425431A (en) 1978-04-20 1984-01-10 Toyo Soda Manufacturing Co., Ltd. Production of an allose-containing polysaccharide
US4312979A (en) 1978-04-20 1982-01-26 Toyo Soda Manufacturing Co., Ltd. Polysaccharides containing allose
JPS6031472B2 (en) 1978-12-14 1985-07-22 協和醗酵工業株式会社 acid uricase
US4251431A (en) 1979-01-16 1981-02-17 Shell Oil Company Lubricating greases
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
DE2916711A1 (en) 1979-04-25 1980-11-06 Behringwerke Ag Blood coagulation factors and process for their manufacture
DE2943016C2 (en) 1979-10-24 1984-09-06 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Process for purifying interferon
JPS5651995A (en) 1979-10-05 1981-05-09 Green Cross Corp:The Preparation of interferon
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
DE3005897A1 (en) 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt GENERAL PRODUCT OF A HIGHER ORGANISM FROM A MICROORGANISM CONTAINING THIS GENE
FR2475900A1 (en) 1980-02-20 1981-08-21 Fabre Sa Pierre VACCINE COMPLEX CONTAINING A SPECIFIC ANTIGEN AND VACCINE CONTAINING SAME
CH651308A5 (en) 1980-07-01 1985-09-13 Hoffmann La Roche INTERFERON AND THEIR PRODUCTION.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS5740503A (en) 1980-08-22 1982-03-06 Seikagaku Kogyo Co Ltd Separation of saccharides
US4315852A (en) 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
FR2497006A1 (en) 1980-12-24 1982-06-25 Ind Electro Ste Gle ELECTRICAL CONTACTS FOR COAXIAL CABLES AND BIFILIC CABLES
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (en) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim SOLUBLE LIVER URICASE, METHOD FOR THE PRODUCTION AND USE THEREOF
US4450103A (en) 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4485176A (en) 1982-06-28 1984-11-27 E. I. Du Pont De Nemours & Company Turbidimetric method for measuring protein in urine and cerebrospinal fluid
EP0109688A3 (en) 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
USD279486S (en) 1983-04-25 1985-07-02 International Jensen Incorporated Controller for a video game or the like
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0671425B2 (en) 1985-06-05 1994-09-14 サッポロビール株式会社 Uricase and method for producing the same
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (en) 1985-06-26 1991-02-07 Cetus Corp SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION.
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
AU597924B2 (en) 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
DD279486A1 (en) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr PROCESS FOR ACTIVATING HYDROXYL GROUP-CONTAINING POLYMER COMPOUNDS
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPS6255079A (en) 1986-04-23 1987-03-10 Mihama Hisaharu Modified uricase
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DD279489A1 (en) 1986-12-11 1990-06-06 Leuna Werke Veb METHOD FOR PRODUCING OPTICALLY TRANSPARENT EPOXY RESIN COMPOSITIONS
JPS63203548A (en) 1987-02-12 1988-08-23 四国化工機株式会社 Sealed vessel for drink and production unit thereof
AU612133B2 (en) 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
AU609824B2 (en) 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1286591C (en) 1987-12-18 1991-07-23 Douglas B. Taylor Apparatus for opening and closing roll-up door
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH01216939A (en) 1988-02-24 1989-08-30 Hoechst Japan Kk Inhibitor for intracranial hemorrhage of immature baby
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5955336A (en) 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
JP3148208B2 (en) 1988-10-31 2001-03-19 富士ゼロックス株式会社 Print server and print system with multiple output trays
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
JPH0354581A (en) 1989-07-24 1991-03-08 Nec Corp Developing cartridge for electrophotographic printer
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5362641A (en) 1989-08-23 1994-11-08 Hadassah Medical Organization Kiryat Hadassah Heparanase derived from human Sk-Hep-1 cell line
JPH03148298A (en) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd Modified peptide and production thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
ES2199935T3 (en) 1991-03-15 2004-03-01 Amgen Inc. PEGILATION OF POLYPEPTIDES.
DE69233690T2 (en) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Delivery device for nebulous drugs
YU66892A (en) 1991-08-20 1995-10-24 Hoechst Ag. PHOSPHOINOSYTOLGLICAN - A PEPTID WITH ACTION AS INSULIN
JP3148298B2 (en) 1991-09-02 2001-03-19 帝人株式会社 Manufacturing method of lightweight composite molding
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
JP3875730B2 (en) 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 Preventive and therapeutic agent for autoimmune diseases
US6385312B1 (en) 1993-02-22 2002-05-07 Murex Securities, Ltd. Automatic routing and information system for telephonic services
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
JPH06255079A (en) 1993-03-08 1994-09-13 Akira Totsuka Screen printing device and method for clothing fabric
US5863534A (en) 1993-04-09 1999-01-26 Bio-Technology General Corp. Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity
DK0696198T3 (en) 1993-04-09 2001-08-06 Bio Technology General Corp Novel polypeptide having inhibitory effect against factor Xa
WO1994023740A1 (en) 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
PT730470E (en) 1993-11-10 2002-08-30 Enzon Inc IMPROVED INTERFERENCE-POLYMER CONJUGATES
US5795776A (en) 1994-03-22 1998-08-18 Bio-Technology General Corp. Expression plasmids regulated by an OSMB promoter
FI96317C (en) 1994-05-31 1996-06-10 Exavena Oy Method for the preparation of finely divided and modified starches
DE4423131A1 (en) 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
US5633227A (en) 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10510516A (en) 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ Polypeptides with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116696A (en) 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
JP2758154B2 (en) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
FR2733914B1 (en) 1995-05-11 1997-08-01 Sanofi Sa STABLE LIQUID COMPOSITION CONTAINING URATE OXYDASE AND LYOPHILIZED COMPOSITION FOR ITS PREPARATION
JPH09154581A (en) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd Substantially pure microorganism capable of producing uricase
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
CN1168495C (en) 1997-01-15 2004-09-29 凤凰药理学公司 Modified tumor necrosis factor
US5816397A (en) 1997-01-21 1998-10-06 Ogio International, Inc. Golf club carrying apparatus
CA2279986A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
KR100369838B1 (en) 1997-02-26 2003-09-29 주식회사 엘지생명과학 Protease as protein derived from nonstructural protein 3 of hepatitis c virus and method for manufacturing the same
US6821763B2 (en) 1997-07-04 2004-11-23 Ajinomoto Co., Inc. Process for producing microbial transglutaminase
JPH1175876A (en) 1997-07-04 1999-03-23 Ajinomoto Co Inc Production of new microbial transglutaminase
ATE274522T1 (en) 1998-06-01 2004-09-15 Genentech Inc SEPARATION OF ANTIBODY MONOMERS FROM THEIR MULTIMERS USING ION EXCHANGE CHROMATOGRAPHY
PL207369B1 (en) 1998-08-06 2010-12-31 Univ Duke Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT2158923E (en) 1998-08-06 2013-06-04 Univ Duke Peg-urate oxidase conjugates and use thereof
US20060188971A1 (en) 1998-08-06 2006-08-24 Duke University Urate oxidase
RU2246318C2 (en) 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Uricase peg-conjugates and their applying
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6429860B1 (en) 1999-06-15 2002-08-06 Visicomp, Inc. Method and system for run-time visualization of the function and operation of a computer program
RU2286711C2 (en) 2000-02-14 2006-11-10 Фёрст Опинион Корпорэйшн System and method for automatic diagnostics
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20050084478A1 (en) 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20020168360A1 (en) 2001-03-02 2002-11-14 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
KR20030043780A (en) 2001-11-28 2003-06-02 주식회사 바이오폴리메드 Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
JP2006517415A (en) 2003-01-09 2006-07-27 ジェネンテック・インコーポレーテッド Purification of polypeptides
JP4273998B2 (en) 2004-02-26 2009-06-03 学校法人東海大学 Sample preparation method for proteome analysis
US20050282877A1 (en) 2004-04-13 2005-12-22 Becker Bryan N Method of decreasing inflammation in kidney transplantion using angiotensin receptor blockers
WO2006017206A2 (en) 2004-07-12 2006-02-16 Tengen Biomedical Company Flavivirus vaccine
GB0420888D0 (en) 2004-09-20 2004-10-20 Photopharmica Ltd Compounds and uses
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
DK3321359T3 (en) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc VARIANT FORMS OF URATOXIDASIS AND ITS USE
BRPI0612942A2 (en) 2005-04-11 2012-10-09 Savient Pharmaceuticals Inc variant form of urate oxidase and its use
US20080159976A1 (en) 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CA2642656A1 (en) 2006-02-22 2007-09-07 Novartis Pharma Ag System for delivering nebulized cyclosporine and methods of treatment
PL2013225T3 (en) 2006-04-12 2015-06-30 Crealta Pharmaceuticals Llc Purification of proteins with cationic surfactant
NL1031926C2 (en) 2006-05-31 2007-12-03 X Flow Bv Device with a bioreactor and membrane filtration module for treating an incoming fluid.
US20080145876A1 (en) 2006-11-21 2008-06-19 University Of Southern California Poly(ethylene glycol) anti-body detection assays and kits for performing thereof
CN101168052A (en) * 2007-10-26 2008-04-30 西安交通大学 Enteric coated preparation for preventing and treating hyperuricemia and gout
TW201016208A (en) 2008-09-15 2010-05-01 Elan Pharm Inc Methods of treatment of hyperuricemia and associated disease states
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CA2764761A1 (en) 2009-06-25 2010-12-29 Savient Pharmaceuticals, Inc. Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout
BRPI1010069A2 (en) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "method for preventing infusion reactions during pegylated uricase therapy in patients; and method for diagnosing whether a patient treated with pegylated uricase will develop infusion reactions or develop antibody-mediated pegylated uricase release without measuring anti-peg antibody titers and pegylated anti-uricase "
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
JP5451464B2 (en) 2010-03-09 2014-03-26 キヤノン株式会社 Charging device
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc Treatment of gout
BR112014010729A2 (en) 2011-11-04 2018-03-20 Cymabay Therapeutics Inc methods for treating gout attacks
JP5888130B2 (en) 2012-06-06 2016-03-16 富士通株式会社 Communication terminal device and communication control method
JP5746101B2 (en) 2012-06-18 2015-07-08 コスメディ製薬株式会社 Rapid dissolution method of microneedles
GB2512876A (en) 2013-04-09 2014-10-15 Image Analysis Ltd Methods and apparatus for quantifying inflammation
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EP3426285B1 (en) 2016-03-11 2024-05-29 Cartesian Therapeutics, Inc. Formulations and doses of pegylated uricase
US20180008665A1 (en) 2016-07-05 2018-01-11 CanTrust LifeScience Corp. Methods of treating and preventing gout and lead nephropathy
CN116637177A (en) 2016-11-11 2023-08-25 好利恩治疗美国公司 Combination therapy of prednisone and uricase molecules and uses thereof
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US20200237880A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2021042055A1 (en) 2019-08-30 2021-03-04 Horizon Pharma Rheumatology Llc Pegloticase for treatment of gout in renal transplant recipients
WO2022035828A1 (en) 2020-08-10 2022-02-17 Horizon Therapeutics Ireland Dac Methods of treating gout

Also Published As

Publication number Publication date
US20160377604A1 (en) 2016-12-29
IL216956A (en) 2016-10-31
CA2766309A1 (en) 2010-12-29
HUP1200205A2 (en) 2012-06-28
MX347903B (en) 2017-05-18
KR101861547B1 (en) 2018-07-02
US10139399B2 (en) 2018-11-27
US20210181187A1 (en) 2021-06-17
US11982670B2 (en) 2024-05-14
EP2446260B1 (en) 2018-12-26
US20180188242A1 (en) 2018-07-05
PL398781A1 (en) 2012-11-19
EP2446260A4 (en) 2013-11-20
US11598767B2 (en) 2023-03-07
AU2010265964A1 (en) 2012-02-02
EP3482768A1 (en) 2019-05-15
US10823727B2 (en) 2020-11-03
WO2010151823A1 (en) 2010-12-29
US20230251247A1 (en) 2023-08-10
HUP1200205A3 (en) 2012-09-28
US20190317083A1 (en) 2019-10-17
RU2535038C2 (en) 2014-12-10
BRPI1010069A2 (en) 2016-03-15
US9377454B2 (en) 2016-06-28
AU2010265964B2 (en) 2014-09-18
RU2012102399A (en) 2013-07-27
NZ597089A (en) 2014-05-30
KR20120046125A (en) 2012-05-09
US11639927B2 (en) 2023-05-02
JP2012531596A (en) 2012-12-10
SG176897A1 (en) 2012-01-30
US20120301454A1 (en) 2012-11-29
MX2011013489A (en) 2012-05-29
US20230028134A1 (en) 2023-01-26
EP2446260A1 (en) 2012-05-02
CZ2011827A3 (en) 2012-09-26
CN102803954A (en) 2012-11-28
JP2015111137A (en) 2015-06-18
IL216956A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
SG10201408480RA (en) Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy
IL260117A (en) Treatment of diseases, disorders or conditions of the lung using placental cells
IL246396B (en) Method for producing a nucleic acid encoding a target protein having enzymatic activity
HK1200838A1 (en) 5-methoxy. 3-oh unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing 5-3-oh
ZA201502161B (en) Detection of non-nucleic acid analytes using strand displacement exchange reactions
EP2201021A4 (en) Alternative nucleic acid sequencing methods
EP2139992A4 (en) A method of modulating the activity of a nucleic acid molecule
EP2167230A4 (en) Co-catalysts for hybrid catalysts, hybrid catalysts comprising same, monocomponent catalysts, methods of manufacture and uses thereof
HK1168627A1 (en) Dna (deoxyribonucleic acid) index library building method based on pcr (polymerase chain reaction)
PL2529033T3 (en) Methods for risk prediction, diagnosis, prognosis of pulmonary disorders
EP2630502A4 (en) Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity
EP2269671A4 (en) Blood sugar level control system
EP2455358A4 (en) Methods for regenerating and maintaining activity of ionic liquid catalyst and producing alkylate
HUE037724T2 (en) Method of treatment based on polymorphisms of the kcnq1 gene
GB2463170B (en) Method for increasing the speed of nucleic acid amplification reactions
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
EP2291237A4 (en) Catalyst for gas-phase contact oxidation of hydrocarbon, preparation method thereof and gas-phase oxidation method of hydrocarbon using the same
DK2262846T3 (en) NEW TITAN-BASED CATALYSTER WITH VERY GOOD ACTIVITY AND SELECTIVITY BY POLYCONDENSATION REACTION
BRPI1008936A2 (en) in vitro method for detecting fibrosis predisposition, diagnosis and / or prognosis and method of selecting a therapeutic compound
HK1165428A1 (en) Assay for detection of human parvovirus nucleic acid
WO2012080359A3 (en) Mhc genes and risk of graft versus host disease
EP2612705A4 (en) Catalyst for selective catalytic reduction, with improved durability
GB2470338B (en) Process for the preparation of 4-(4-hydroxyphenyl)butan-2-one using solid acid clay catalyst
IL201170A0 (en) Measurement of the activity of a kynurenine-converting enzyme and/or of a kynurenic acid, anthranilic acid and/or 3-hydoxykynurenine-producing enzyme
EP2488020A4 (en) 3-substituted compounds for reducing uric acid